Drug Approval | June 27, 2024
Shilpa Medicare Bio Analytical unit gets "No Action Indicated" classification from USFDA
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
Renews GMP certifications for India and Malaysia sites
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
Shelter Pharma Limited secured an order from Berlin International Medical Co D3Cure 50 ml x 30000 pcs
This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
Greg was also central to the planning, design, and construction of this facility
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Subscribe To Our Newsletter & Stay Updated
